The Diabeo software enabling individualized insulin dose adjustments combined with telemedicine support improves HbA1c in poorly controlled type 1 diabetic patients: a 6-month, randomized, open-label, parallel-group, multicenter trial (TeleDiab 1 Study).
Setting: France, 17 hospital sites
Follow up: 6 months
Total: 180 (173)
IG1: 60 (56)
IG2: 59 (57)
CG: 61 (60)
– Diabetes type 1
– HbA1c ≥ 8.0%
App “electronic logbook” (Diabeo)
– Feedback on data (algorithms)
– Data transmission to medical staff
IG1: Electronic logbook but no teleconsultation. Face to face follow up at 3 and 6 months.
IG2: Electronic logbook and teleconsultations (phone call) every 2 week. Teleconsultations were focused on insulin dose adjustments and motivational support.
Add on: –
no electronic logbook/app, follow up visits at hospital after 3 and 6 months.
IG1 ↓ IG2↓
– HBA1c ≤ 7.5%
IG1 → IG2↓
No difference in the frequency of symptomatic, nonsevere hypoglycemia episodes.
Patient experiences: 73% (IG2) stated that they wanted to continue with the app.
Time spend on travelling to hospital, administrative procedures,
and waiting time:
CG: 274 min
– Doctors average time spend on consultations:
IG2=72 min (tele)
– Mean number of teleconsultations: 8.7
– Mean duration for one teleconsultation: 7.4 min.
Home monitoring equipment
– Blood glucose
– Blood pressure
– test strips (glucose)
– staff for monitoring and phonecalls/sms
Health care utilization: